triazoles has been researched along with Metabolic Syndrome in 19 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (21.05) | 29.6817 |
| 2010's | 14 (73.68) | 24.3611 |
| 2020's | 1 (5.26) | 2.80 |
| Authors | Studies |
|---|---|
| Alenina, N; Bader, M; Dias-Júnior, NM; Eleutério-Silva, MA; Ferreira-Neves, VP; Moura, FA; Nunes-Souza, V; Rabelo, LA | 1 |
| Abu Jhaisha, S; Becker, W; Kii, I; Knapp, S; Papadopoulos, C; Sonamoto, R; Widowati, EW | 1 |
| Bábíčková, J; Borbélyová, V; Celec, P; Domonkos, E; Hodosy, J; Kačmárová, M; Ostatníková, D; Tóthová, Ľ; Uličná, O | 1 |
| Diamant, M; Heymans, MW; Mari, A; Muskiet, MH; Ouwens, DM; Pouwels, PJ; van Genugten, RE; van Raalte, DH | 1 |
| Bardou-Jacquet, E; Beaumont-Epinette, MP; Ben Ali, Z; Brissot, P; Jouanolle, AM; Loreal, O | 1 |
| Akcali, KC; Amber, CF; Belma, T; Bozkus, Y; Can, AK; Cicek, FA; Evren, O; Ozcinar, E; Tokcaer-Keskin, Z; Turan, B; Yusuf, B; Zeynep, TK | 1 |
| Khera, AV; Millar, JS; Rader, DJ; Ruotolo, G; Wang, MD | 1 |
| Bloedon, LT; Duffy, D; Dunbar, RL; Fuki, IV; Gadi, R; Harris, CJ; Howey, DC; McCoy, M; Millar, JS; Movva, R; Rader, DJ; Shah, A; Wang, MD; Wolfe, ML | 1 |
| Bilan, VP; Jackson, EK; Tofovic, DS | 1 |
| Aguila, MB; Cardoso-de-Lemos, FS; de Carvalho, L; Gregório, BM; Mandarim-de-Lacerda, CA; Souza-Mello, V | 1 |
| Jackson, EK | 1 |
| Brown, NJ; Byrne, L; Kunchakarra, S; Marney, A | 1 |
| Borelli, MI; Del Zotto, H; Flores, LE; Francini, F; Gagliardino, JJ; Madrid, VG; Maiztegui, B; Massa, ML; Raschia, MA; Rebolledo, OR | 1 |
| Balkovec, J; Dragovic, J; Leeman, A; Lyons, K; Maletic, M; Mundt, SS; Shah, K; Szymonifka, M; Thieringer, R; Vosatka, AH; Waddell, ST; Zokian, HJ | 1 |
| Avogaro, A; de Kreutzenberg, SV; Fadini, GP; Gjini, R | 1 |
| Aster, SD; Balkovec, JM; Brown, K; Carbin, L; Graham, DW; Hermanowski-Vosatka, A; LeGrand, CB; Mundt, SS; Olson, S; Robbins, MA; Schaeffer, JM; Slossberg, LH; Szymonifka, MJ; Thieringer, R; Wright, SD | 1 |
| Balkovec, JM; Dragovic, J; Gu, X; Hermanowski-Vosatka, A; Koo, GC; Koprak, SL; LeGrand, C; Mundt, SS; Shah, K; Springer, MS; Tan, EY; Thieringer, R; Waddell, ST; Zokian, HJ | 1 |
| Aster, SD; Balkovec, JM; Graham, DW; Hermanowski-Vosatka, A; Kharbanda, D; Mundt, SS; Patel, G; Ponpipom, M; Santorelli, GM; Shah, K; Springer, MS; Szymonifka, MJ; Thieringer, R; Wright, SD; Xiao, J; Zokian, H | 1 |
1 review(s) available for triazoles and Metabolic Syndrome
| Article | Year |
|---|---|
Non-HFE hemochromatosis: pathophysiological and diagnostic aspects.
Topics: Alcohol Drinking; Benzoates; Biopsy; Cataract; Cation Transport Proteins; Decision Trees; Deferasirox; Diet; Gaucher Disease; Genetic Testing; Hemochromatosis; Hemochromatosis Protein; Hepcidins; Histocompatibility Antigens Class I; Humans; Inflammation; Iron; Iron Chelating Agents; Iron Metabolism Disorders; Iron Overload; Liver; Macrophage Activation Syndrome; Magnetic Resonance Imaging; Membrane Proteins; Metabolic Syndrome; Mutation; Phlebotomy; Receptors, Transferrin; Transferrin; Triazoles | 2014 |
5 trial(s) available for triazoles and Metabolic Syndrome
| Article | Year |
|---|---|
Does dipeptidyl peptidase-4 inhibition prevent the diabetogenic effects of glucocorticoids in men with the metabolic syndrome? A randomized controlled trial.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Fasting; Glucocorticoids; Glucose Intolerance; Humans; Insulin Resistance; Islets of Langerhans; Male; Metabolic Syndrome; Middle Aged; Postprandial Period; Prednisolone; Pyrazines; Sitagliptin Phosphate; Triazoles | 2014 |
Potent peroxisome proliferator-activated receptor-α agonist treatment increases cholesterol efflux capacity in humans with the metabolic syndrome.
Topics: Apolipoprotein A-I; Apolipoproteins B; Cholesterol, HDL; Female; Humans; Male; Metabolic Syndrome; Middle Aged; PPAR alpha; Propionates; Triazoles | 2015 |
Potent and selective PPAR-alpha agonist LY518674 upregulates both ApoA-I production and catabolism in human subjects with the metabolic syndrome.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Apolipoprotein A-I; Cholesterol, HDL; Cholesterol, VLDL; Deuterium; Double-Blind Method; Female; Humans; Kinetics; Male; Metabolic Syndrome; Middle Aged; Placebos; PPAR alpha; Propionates; Triazoles; Triglycerides; Young Adult | 2009 |
Interactive hemodynamic effects of dipeptidyl peptidase-IV inhibition and angiotensin-converting enzyme inhibition in humans.
Topics: Adult; Aldosterone; Angiotensin-Converting Enzyme Inhibitors; Blood Glucose; Blood Pressure; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dose-Response Relationship, Drug; Double-Blind Method; Drug Interactions; Drug Therapy, Combination; Enalapril; Female; Heart Rate; Hemodynamics; Humans; Insulin; Male; Metabolic Syndrome; Middle Aged; Peptidyl-Dipeptidase A; Prospective Studies; Pyrazines; Renal Circulation; Sitagliptin Phosphate; Sodium; Triazoles | 2010 |
The metabolic syndrome influences the response to incretin-based therapies.
Topics: Adamantane; Aged; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Female; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Incretins; Male; Metabolic Syndrome; Middle Aged; Nitriles; Peptides; Prognosis; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Treatment Outcome; Triazoles; Venoms; Vildagliptin | 2011 |
13 other study(ies) available for triazoles and Metabolic Syndrome
| Article | Year |
|---|---|
3-Amino-1,2,4-Triazole Induces Quick and Strong Fat Loss in Mice with High Fat-Induced Metabolic Syndrome.
Topics: Animals; Body Weight; Disease Models, Animal; Male; Metabolic Syndrome; Mice; Triazoles | 2020 |
DYRK1B mutations associated with metabolic syndrome impair the chaperone-dependent maturation of the kinase domain.
Topics: Catalytic Domain; Cell Cycle Proteins; Chaperonins; Dyrk Kinases; HeLa Cells; Humans; Metabolic Syndrome; Mutation; Phosphorylation; Protein Conformation; Protein Domains; Protein Folding; Protein Serine-Threonine Kinases; Protein-Tyrosine Kinases; Triazoles; Tyrosine | 2017 |
Does long-term androgen deficiency lead to metabolic syndrome in middle-aged rats?
Topics: Age Factors; Andropause; Animals; Aromatase Inhibitors; Biomarkers; Blood Glucose; Blood Pressure; Cholesterol; Disease Models, Animal; Estradiol; Female; Hormone Replacement Therapy; Hypogonadism; Letrozole; Liver; Liver Diseases; Male; Metabolic Syndrome; Nitriles; Orchiectomy; Ovariectomy; Rats, Inbred Lew; Sex Factors; Sexual Development; Testosterone; Triazoles; Uric Acid | 2017 |
Di-peptidyl peptidase-4 inhibitor sitagliptin protects vascular function in metabolic syndrome: possible role of epigenetic regulation.
Topics: Analysis of Variance; Animals; Aorta; Blotting, Western; Dipeptidyl-Peptidase IV Inhibitors; Epigenesis, Genetic; Fluorescent Antibody Technique; Histones; Metabolic Syndrome; Pyrazines; Rats; Sitagliptin Phosphate; Sucrose; Triazoles; Vasodilation | 2014 |
Sitagliptin augments angiotensin II-induced renal vasoconstriction in kidneys from rats with metabolic syndrome.
Topics: Angiotensin II; Animals; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Dipeptidyl-Peptidase IV Inhibitors; Glycated Hemoglobin; Hypertension; Kidney; Male; Metabolic Syndrome; Proteinuria; Pyrazines; Rats; Rats, Inbred SHR; Rats, Inbred WKY; Renal Circulation; Sitagliptin Phosphate; Triazoles; Vasoconstriction; Vasoconstrictor Agents | 2010 |
Comparative effects of telmisartan, sitagliptin and metformin alone or in combination on obesity, insulin resistance, and liver and pancreas remodelling in C57BL/6 mice fed on a very high-fat diet.
Topics: Adipocytes; Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Benzoates; Dietary Fats; Dipeptidyl-Peptidase IV Inhibitors; Drug Evaluation, Preclinical; Drug Therapy, Combination; Energy Intake; Glucose Tolerance Test; Hypoglycemic Agents; Insulin Resistance; Liver; Male; Metabolic Syndrome; Metformin; Mice; Mice, Inbred C57BL; Obesity; Pancreas; Pyrazines; Sitagliptin Phosphate; Telmisartan; Triazoles | 2010 |
Dipeptidyl peptidase IV inhibition alters the hemodynamic response to angiotensin-converting enzyme inhibition in humans with the metabolic syndrome.
Topics: Angiotensin-Converting Enzyme Inhibitors; Blood Pressure; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Drug Therapy, Combination; Enalapril; Heart Rate; Hemodynamics; Humans; Metabolic Syndrome; Models, Biological; Peptidyl-Dipeptidase A; Pyrazines; Sitagliptin Phosphate; Triazoles | 2010 |
Sitagliptin prevents the development of metabolic and hormonal disturbances, increased β-cell apoptosis and liver steatosis induced by a fructose-rich diet in normal rats.
Topics: Animals; Apoptosis; Blood Glucose; Body Weight; Diet; Dipeptidyl-Peptidase IV Inhibitors; Drinking; Drug Evaluation, Preclinical; Eating; Exenatide; Fatty Liver; Fructose; Glucose Tolerance Test; Hypoglycemic Agents; Insulin-Secreting Cells; Male; Metabolic Syndrome; Peptides; Pyrazines; Rats; Rats, Wistar; Sitagliptin Phosphate; Triazoles; Venoms | 2011 |
Bicyclo[2.2.2]octyltriazole inhibitors of 11β-hydoxysteroid dehydrogenase type 1. Pharmacological agents for the treatment of metabolic syndrome.
Topics: 11-beta-Hydroxysteroid Dehydrogenase Type 1; 11-beta-Hydroxysteroid Dehydrogenase Type 2; Animals; Bridged Bicyclo Compounds; Enzyme Inhibitors; Humans; Metabolic Syndrome; Mice; Structure-Activity Relationship; Triazoles | 2011 |
[Nephropathy and metabolic heart diseases. Cardiac risk in kidney malfunction].
Topics: Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Dose-Response Relationship, Drug; Humans; Kidney Failure, Chronic; Metabolic Syndrome; Pyrazines; Randomized Controlled Trials as Topic; Renal Dialysis; Risk Factors; Sitagliptin Phosphate; Survival Rate; Triazoles | 2012 |
Adamantyl triazoles as selective inhibitors of 11beta-hydroxysteroid dehydrogenase type 1.
Topics: 11-beta-Hydroxysteroid Dehydrogenase Type 1; Adamantane; Animals; Enzyme Inhibitors; Humans; Inhibitory Concentration 50; Metabolic Syndrome; Mice; Pharmacokinetics; Structure-Activity Relationship; Triazoles | 2005 |
Discovery of 4-heteroarylbicyclo[2.2.2]octyltriazoles as potent and selective inhibitors of 11beta-HSD1: novel therapeutic agents for the treatment of metabolic syndrome.
Topics: 11-beta-Hydroxysteroid Dehydrogenase Type 1; Animals; Enzyme Inhibitors; Humans; Metabolic Syndrome; Mice; Triazoles | 2005 |
Bis-aryl triazoles as selective inhibitors of 11beta-hydroxysteroid dehydrogenase type 1.
Topics: 11-beta-Hydroxysteroid Dehydrogenase Type 1; Animals; Binding Sites; Disease Models, Animal; Enzyme Inhibitors; Hydrocarbons, Aromatic; Hypoglycemic Agents; Inhibitory Concentration 50; Metabolic Syndrome; Mice; Models, Chemical; Structure-Activity Relationship; Triazoles | 2008 |